美国食品药品监督管理局针对促红细胞生成素的黑框警告：肾病学家该怎么做？ - Suppr

Suppr

超能文献

The FDA black box for EPO: what should nephrologists do?

作者信息

Singh Ajay K

机构信息

Renal Division, Brigham and Women's Hospital, Boston, USA.

出版信息

Nephrol News Issues. 2007 May;21(6):55-6, 58-9.

PMID:17518125

Abstract

摘要

相似文献

The FDA black box for EPO: what should nephrologists do?

Nephrol News Issues. 2007 May;21(6):55-6, 58-9.

The FDA, stocks, black boxes and ESAs.

Nephrol News Issues. 2007 May;21(6):53-4.

Managing anemia: what do we do now?

Nephrol News Issues. 2007 May;21(6):50, 52.

Reaction from renal associations. Renal Physicians Association.

Nephrol News Issues. 2007 May;21(6):61-2, 64.

Safety concerns for two big anemia drugs.

Nursing. 2008 Oct;38(10):12. doi: 10.1097/01.NURSE.0000337213.09431.6a.

Reevaluating erythropoiesis-stimulating agents.

N Engl J Med. 2010 May 6;362(18):1743; author reply 1743-4.

New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.

J Support Oncol. 2007 Nov-Dec;5(10):471-3.

Erythropoietin: the swinging pendulum.

Leuk Res. 2012 Aug;36(8):939-44. doi: 10.1016/j.leukres.2012.04.017. Epub 2012 May 11.

Reevaluating erythropoiesis-stimulating agents.

N Engl J Med. 2010 May 6;362(18):1742; author reply 1743-4. doi: 10.1056/NEJMc1002263.

FDA finalizes REMS program for ESAs; Amgen continues to study risks.

J Natl Cancer Inst. 2010 May 5;102(9):592-3. doi: 10.1093/jnci/djq162. Epub 2010 Apr 26.

引用本文的文献

The effect of empowerment on the self-efficacy, quality of life and clinical and laboratory indicators of patients treated with hemodialysis: a randomized controlled trial.

Health Qual Life Outcomes. 2012 Sep 20;10:115. doi: 10.1186/1477-7525-10-115.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The FDA black box for EPO: what should nephrologists do?

Nephrol News Issues. 2007 May;21(6):55-6, 58-9.

The FDA, stocks, black boxes and ESAs.

Nephrol News Issues. 2007 May;21(6):53-4.

Managing anemia: what do we do now?

Nephrol News Issues. 2007 May;21(6):50, 52.

Reaction from renal associations. Renal Physicians Association.

Nephrol News Issues. 2007 May;21(6):61-2, 64.

Safety concerns for two big anemia drugs.

Nursing. 2008 Oct;38(10):12. doi: 10.1097/01.NURSE.0000337213.09431.6a.

Reevaluating erythropoiesis-stimulating agents.

N Engl J Med. 2010 May 6;362(18):1743; author reply 1743-4.

New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.

J Support Oncol. 2007 Nov-Dec;5(10):471-3.

Erythropoietin: the swinging pendulum.

Leuk Res. 2012 Aug;36(8):939-44. doi: 10.1016/j.leukres.2012.04.017. Epub 2012 May 11.

Reevaluating erythropoiesis-stimulating agents.

N Engl J Med. 2010 May 6;362(18):1742; author reply 1743-4. doi: 10.1056/NEJMc1002263.

FDA finalizes REMS program for ESAs; Amgen continues to study risks.

J Natl Cancer Inst. 2010 May 5;102(9):592-3. doi: 10.1093/jnci/djq162. Epub 2010 Apr 26.

引用本文的文献

The effect of empowerment on the self-efficacy, quality of life and clinical and laboratory indicators of patients treated with hemodialysis: a randomized controlled trial.

Health Qual Life Outcomes. 2012 Sep 20;10:115. doi: 10.1186/1477-7525-10-115.